Literature DB >> 34145489

Oral health condition in cancer patients under bisphosphonate therapy.

Rogério Jardim Caldas1,2, Héliton Spíndola Antunes3, Camila de Oliveira Rodini Pegoraro4, Fábio Ribeiro Guedes5, Paulo Sérgio da Silva Santos6.   

Abstract

OBJECTIVES: To investigate the association of oral health condition with the occurrence of medication-related osteonecrosis of the jaw (MRONJ) in a cancer population.
METHODS: A multicenter cross-sectional study was conducted with cancer patients exposed to bisphosphonates for at least 7 months. Dental and periodontal conditions were assessed by epidemiological indices.
RESULTS: The sample consisted of 80 patients under bisphosphonate therapy, nine of which were allocated to group 1 (with MRONJ) and 71 to group 2 (without MRONJ). Osteonecrosis cases presented 19 decayed, missing, and filled teeth on average. Moderate gingival inflammation was noted in both groups and together with severe inflammation exceeded 50% of the groups. The presence of dental calculus was detected in about half of the individuals in both groups. Shallow periodontal pockets were detected in about 25% of both groups. Deep periodontal pockets were more prevalent among patients with osteonecrosis. Regular oral hygiene was detected in approximately 25% of individuals in both groups. There was a strong positive correlation between the clinical staging of osteonecrosis and decayed, missing, and filled teeth index (DMFTI).
CONCLUSIONS: Patients had a poor oral health condition. All but one osteonecrosis case had no previous history of tooth extraction; oral infections seemed to play a major role in the development of bone necrosis. Advanced osteonecrosis stages were associated with a higher DMFTI.

Entities:  

Keywords:  Caries; Epidemiology; Oncology; Oral hygiene; Osteonecrosis; Periodontal disease(s)/periodontitis

Year:  2021        PMID: 34145489     DOI: 10.1007/s00520-021-06362-y

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  32 in total

1.  PERIODONTAL DISEASE IN PREGNANCY. I. PREVALENCE AND SEVERITY.

Authors:  H LOE; J SILNESS
Journal:  Acta Odontol Scand       Date:  1963-12       Impact factor: 2.331

2.  THE SIMPLIFIED ORAL HYGIENE INDEX.

Authors:  J C GREENE; J R VERMILLION
Journal:  J Am Dent Assoc       Date:  1964-01       Impact factor: 3.634

3.  Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.

Authors:  Meletios A Dimopoulos; Efstathios Kastritis; Athanasios Anagnostopoulos; Ioannis Melakopoulos; Dimitra Gika; Lia A Moulopoulos; Christina Bamia; Evangelos Terpos; Konstantinos Tsionos; Aristotelis Bamias
Journal:  Haematologica       Date:  2006-06-01       Impact factor: 9.941

4.  Osteonecrosis of the jaw and bisphosphonates.

Authors:  Brian G M Durie; Michael Katz; John Crowley
Journal:  N Engl J Med       Date:  2005-07-07       Impact factor: 91.245

5.  Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents.

Authors:  Ourania Nicolatou-Galitis; Erofili Papadopoulou; Emmanouil Vardas; Maria Kouri; Dimitra Galiti; Evangelos Galitis; Konstantina-Eleni Alexiou; Kostas Tsiklakis; Alexandros Ardavanis; Evangelia Razis; Ilias Athanasiadis; Stavroula Droufakou; Amanda Psyrri; Michalis V Karamouzis; Helena Linardou; Danai Daliani; Dimitrios Tzanninis; Sotirios Sachanas; Konstantinos Laschos; Marie-Christine Kyrtsonis; Fotini Antoniou; Apostolos Laskarakis; Styllianos Giassas; Adamantia Nikolaidi; George Rigakos; Anna Ntokou; Cesar A Migliorati; Carla I Ripamonti
Journal:  Oral Dis       Date:  2020-03-03       Impact factor: 3.511

6.  Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.

Authors:  Aristotle Bamias; Efstathios Kastritis; Christina Bamia; Lia A Moulopoulos; Ioannis Melakopoulos; George Bozas; Vassiliki Koutsoukou; Dimitra Gika; Athanasios Anagnostopoulos; Christos Papadimitriou; Evagelos Terpos; Meletios A Dimopoulos
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

7.  Incidence and risk factors of bisphosphonate-associated osteonecrosis of the jaws.

Authors:  Matthew R Stumpe; Rakesh K Chandra; Furhan Yunus; Sandeep Samant
Journal:  Head Neck       Date:  2009-02       Impact factor: 3.147

8.  Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies.

Authors:  Thacharot Boonyapakorn; Ingrid Schirmer; Peter A Reichart; Isrid Sturm; Gero Massenkeil
Journal:  Oral Oncol       Date:  2008-02-20       Impact factor: 5.337

9.  Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.

Authors:  Christian Walter; Bilal Al-Nawas; Knut A Grötz; Christian Thomas; Joachim W Thüroff; Viktoria Zinser; Heinold Gamm; Joachim Beck; Wilfried Wagner
Journal:  Eur Urol       Date:  2008-06-26       Impact factor: 20.096

10.  Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.

Authors:  Konstantinos Vahtsevanos; Athanassios Kyrgidis; Evgenia Verrou; Eirini Katodritou; Stefanos Triaridis; Charalampos G Andreadis; Ioannis Boukovinas; Georgios E Koloutsos; Zisis Teleioudis; Kyriaki Kitikidou; Panagiotis Paraskevopoulos; Konstantinos Zervas; Konstantinos Antoniades
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

View more
  1 in total

1.  One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ).

Authors:  Vittorio Fusco; Giuseppina Campisi; Alberto Bedogni
Journal:  Support Care Cancer       Date:  2022-03-21       Impact factor: 3.359

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.